Fredun Pharmaceuticals Ltd Financials
Company Logo

Fredun Pharmaceuticals Ltd Financial Statement

Fredun Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue107.35
Operating Expense93.40
Net Profit4.27
Net Profit Margin3.98
Earning Per Share9.05
EBIDTA13.94
Effective Tax Rate23.66

Fredun Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual348.16
Operating Expenses Annual310.17
Operating Profit Annual38.90
Interest Annual13.65
Depreciation3.80
Net Profit Annual15.62
Tax Annual5.83

Fredun Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning3.44
Cash Flow from Operations-0.44
Cash Flow from Investing-7.64
Cash Flow from Financing5.99
Cash Flow at the End1.35

Fredun Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)11.17
PBIT Margin (%)10.08
PBT Margin (%)9.34
Net PROFIT Margin (%)4.49
Return On Networth / Equity (%)14.34
Return On Networth /Employed (%)16.95
Return On Assets (%)7.54
Total Debt / Equity (X)0.88
Asset Turnover Ratio (%)1.68

Fredun Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual46.57
Total Current Assets Annual257.20
Non Current Assets Annual50.40
Total Shareholders Funds Annual121.47
Total Assets Annual307.60

Fredun Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Fredun Pharmaceuticals Ltd has a market capitalization of 337.07 Cr. Value Research classifies it as a Small-Cap company.
No, Fredun Pharmaceuticals Ltd is not debt-free with a debt-to-equity ratio of 0.87.
In FY 2023 , Fredun Pharmaceuticals Ltd recorded a total revenue of approximately 346.58 Cr marking a significant milestone in the company's financial performance.
Fredun Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.2% annually, respectively..
Fredun Pharmaceuticals Ltd's current PE ratio is 21.58.
Fredun Pharmaceuticals Ltd's ROCE averaged 13.7% from the FY ending March 2022 to 2024, with a median of 14.6%. It peaked at 15.5% in March 2024, reflecting strong capital efficiency over the period..
Fredun Pharmaceuticals Ltd's latest EBIT is Rs. 35.10 Cr, surpassing the average EBIT of Rs. 25.05 Cr over the 5 years..